Medical Cannabis for Arthritis Pain: What the Evidence Really Shows
Despite promising preclinical and observational evidence, medical cannabis rheumatic pain treatment lacks high-quality clinical trials. This 2024 review highlights the gap between patient use and clinical evidence. Clinicians should engage patients…
CBD and Anxiety: Promising Signal, Weak Evidence Base
The cbd anxiety clinical trials 2024 review reveals most studies are exploratory with varied designs and small samples. Evidence supporting CBD for anxiety disorders remains weak and inconclusive. This review highlights the urgent need for robust…
Opioids and Cannabinoids for Neurologic Pain: What Neurologists Need to Know in 2024
This 2024 CME review focuses on opioid therapy neurologic pain, synthesizing current evidence and guidelines for neurologists. It highlights risks of abrupt opioid tapering and the investigational role of cannabinoids. The review supports a cautious,…
CB2 Receptors in the Brain: A Promising but Unproven Anti-Inflammatory Target
CB2 receptor neuroinflammation is a promising target in neurodegenerative diseases such as Alzheimer's and Parkinson's. Preclinical studies show CB2 activation reduces brain inflammation and protects neurons. However, clinical evidence for CB2 receptor…
Prevalence and Correlates of Past-year Kratom Use Among US Adults
This kratom epidemiology mental health survey examines the prevalence and correlates of past-year kratom use among US adults. Findings highlight higher use in populations with psychological distress and depression. The study provides critical baseline…
Nonswallowed Kratom-Derived Products: Unlawful Dietary Supplements That Endanger Public Health.
Kratom regulatory safety is critical as non-oral kratom products bypass FDA oversight and violate dietary supplement laws. These unlawful formulations may endanger public health due to unknown safety profiles. Clinicians should be aware of these risks…
GPR3 in Neuro-Metabolic-Immune-Reproductive Nexus: Potential Therapeutic Target
GPR3 neuro-metabolic immune nexus represents a promising therapeutic target for multisystem diseases. This receptor influences neurological, metabolic, immune, and reproductive functions. Understanding GPR3's role may guide future cannabinoid therapies.
Local Therapeutic Strategies for Neurocutaneous Dysesthesia: From Capsaicin to Cannabinoids
Local therapeutic strategies neurocutaneous dysesthesia focus on topical treatments such as capsaicin and cannabinoids to manage abnormal skin sensations. These approaches provide targeted relief with fewer systemic effects. This review highlights…
Anticancer Potential of Cannabidiol in Renal Cell Carcinoma: Serum Modulation and Preliminary Mechanistic Insights.
This study explores the anticancer potential cannabidiol renal cell carcinoma effects through serum modulation. Preliminary mechanistic insights provide a foundation for further research. The findings highlight the need for cautious interpretation in…
Advances in Targeting Amyloid Beta Aggregation and Neuroinflammation in Alzheimer’s
Amyloid beta aggregation Alzheimer's disease is a key pathological mechanism driving cognitive decline. This article reviews advances in targeting amyloid beta aggregation and neuroinflammation. Natural products like curcumin show potential but require…
